NOB1 Gene as a Potential Biomarker in Clinical Outcomes and Prognosis of Patients with Gastric Cancer

Abstract

Background: To investigate relationship of the Nin one binding protein (NOB1) gene with the prognosis of gastric cancer (GC). Methods: The GC tumor tissues and paired adjacent normal gastric tissues were collected from 65 patients who underwent primary gastric resection surgery in our hospital from January 2009 to July 2011. Data including age, gender, family cancer history, tumor diameter, pathological type, differentiation, clinical stage by tumor node metastasis (TNM) staging, lymphatic metastasis, and distant metastasis were collected. Expression of NOB1 and VEGF was determined using real time PCR. The relationship of NOB1 with clinical outcomes and prognosis of GC patients was analyzed by statistical methods. Results: Both mRNA expression of NOB1 and VEGF was significantly higher in tumor tissues than that of the normal tissues, p < 0.05, and mRNA expression of NOB1 was positively correlated with mRNA expression of VEGF by Pearson's correlation analysis. Significant difference was observed in TNM stage, tumor differentiation, and metastasis between the low and high NOB1 expression groups, p < 0.05, while no significant difference was observed in age, gender, family cancer history, tumor location, and diameter. Univariate analysis showed that TNM stage, tumor differentiation, lymphatic metastasis, distant metastasis and expression of NOB1 and VEGF were all significantly different in survival and dead patients. Logistic analysis showed that NOB1 was an independent risk factor for 5-year mortality of GC patients, as well as lymphatic metastasis and distant metastasis. Conclusions: NOB1 was correlated with clinical outcomes and prognosis of GC patients and was an independent risk factor for 5-year mortality of GC patients. This study might provide more clinical evidences for NOB1 in GC and give a new target for diagnosis and treatment for GC patients.

RETRACTED: MicroRNA‐612 inhibits cervical cancer progression by targeting NOB1

“…Among the targets, NOB1 was chosen as a subject of study based on its biological function. 21,22 NOB1 was reportedly linked to the onset and development of various tumours and plays the role of an oncogene. [23][24][25][26][27] A previous study showed that NOB1 levels were elevated in cervical cancer tissues and cell lines.…”

“…To investigate how miR‐612 inhibits cervical cancer, its potential targets were identified by bioinformatics analysis. Among the targets, NOB1 was chosen as a subject of study based on its biological function …”

hsa_circ0021347 as a Potential Target Regulated by B7-H3 in Modulating the Malignant Characteristics of Osteosarcoma

“…In 2014, Li et al reported that miR-646 could inhibit tumorigenesis of renal cancer cells through the modulation of NOB1 and thus influence the MAPK pathway in renal cancer [57]. In addition, a series of studies showed the importance of NOB1 in multitumor development, including papillary thyroid cancer [58], glioblastoma [59], gastric cancer [60], and osteosarcoma [61]. Recently, Liu et al showed that the miR-646/NOB1 axis might play an important role in the development of OS and facilitate the colony formation, migration, and invasion ability of OS cells [26].…”

<p>MiR-326: Promising Biomarker for Cancer</p>

“…As a member of the ETS oncogene family, ELK1 affects cytoskeleton transformation and tumor invasion 32,33. As a conserved protein, nin one binding 1 (NOB1) affects RNA metabolism and protease function 34,35. In osteosarcoma, glioma and colorectal cancer, miR-326 can target NOB1 to inhibit metastasis 16,36,37.…”